Are you Dr. Eckhardt?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 54 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1601 Trinity St
Austin, TX 78712Phone+1 512-495-5512- Is this information wrong?
Summary
- Dr. Sue Eckhardt, MD is an oncologist in Austin, Texas. She is currently licensed to practice medicine in Texas, Colorado, and California. She is affiliated with Ascension Seton Medical Center Austin.
Education & Training
- Scripps Clinic/Scripps Green HospitalFellowship, Medical Oncology, 1988 - 1990
- University of Virginia Medical CenterInternship, Internal Medicine, 1985 - 1986
- University of Texas Medical Branch School of MedicineClass of 1985
Certifications & Licensure
- CA State Medical License 1988 - Present
- TX State Medical License 1993 - 2024
- CO State Medical License 1999 - 2019
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- America's Top Doctors for Cancer Castle Connolly, 2006-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas Start of enrollment: 2006 Mar 01
- Collection and Storage of Tissue and Blood Samples From Patients With Cancer Start of enrollment: 2015 May 19
Publications & Presentations
PubMed
- 1 citationsPopulation-level comparisons of gene regulatory networks modeled on high-throughput single-cell transcriptomics data.Daniel Osorio, Anna Capasso, S Gail Eckhardt, Uma Giri, Alexander Somma, Todd M Pitts, Christopher H Lieu, Wells A Messersmith, Stacey M Bagby, Harinder Singh, Jishnu ...> ;Nature Computational Science. 2024 Mar 4
- First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.Schreiber, A., Kagihara, J., Corr, B., Davis, S., Lieu, C., Kim, S., Jimeno, A., Camidge, D., Williams, J., Heim, A., Martin, A., DeMattei, J., Holay, N., Triplett, T....> ;Cancers. 2023 Dec 23
- 1 citationsElucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy.Nisha Holay, Alexander Somma, Mark Duchow, Milad Soleimani, Anna Capasso, Srividya Kottapalli, Joshua Rios, Uma Giri, Jennifer Diamond, Anna Schreiber, Anthony D Pisco...> ;Frontiers in Immunology. 2023 Jan 1
- Join now to see all
Hospital Affiliations
- Ascension Seton Medical Center AustinAustin, Texas